第一医药
(600833)
| 流通市值：25.63亿 | | | 总市值：25.63亿 |
| 流通股本：2.23亿 | | | 总股本：2.23亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 484,557,342.69 | 2,130,234,461.61 | 1,539,077,117.96 | 996,596,339.46 |
| 营业收入 | 484,557,342.69 | 2,130,234,461.61 | 1,539,077,117.96 | 996,596,339.46 |
| 二、营业总成本 | 484,521,297.47 | 2,128,144,034.15 | 1,536,044,900.73 | 994,289,666.33 |
| 营业成本 | 413,361,914.44 | 1,788,731,205.8 | 1,288,442,006.6 | 831,770,568.01 |
| 税金及附加 | 994,906.87 | 6,021,156.28 | 3,937,031.53 | 2,658,425.62 |
| 销售费用 | 57,907,426.53 | 269,075,457.85 | 196,754,286.65 | 134,637,834.62 |
| 管理费用 | 14,489,534.65 | 71,611,599.26 | 53,111,893.27 | 29,804,790.93 |
| 财务费用 | -2,232,485.02 | -7,295,385.04 | -6,200,317.32 | -4,581,952.85 |
| 其中:利息费用 | 815,886.47 | 4,511,691.31 | 3,491,717.83 | 2,382,139.34 |
| 其中:利息收入 | 3,165,815.15 | 14,013,542.17 | 10,720,198.73 | 7,124,179.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -11,419.67 | - | - |
| 加:投资收益 | 780,609.08 | 11,073,990.93 | 8,958,685.78 | 8,489,595.84 |
| 资产处置收益 | 29,638,332.94 | 50,179,480.75 | 49,608,254.64 | 404,944.23 |
| 资产减值损失(新) | - | -1,648,594.19 | - | - |
| 信用减值损失(新) | 633,744 | -658,221.93 | 1,447,863.97 | 1,396,756.29 |
| 其他收益 | 200,112.65 | 13,717,064.35 | 408,403.32 | 292,042.29 |
| 四、营业利润 | 31,288,843.89 | 74,742,727.7 | 63,455,424.94 | 12,890,011.78 |
| 加:营业外收入 | 4,674.33 | 2,992,630.1 | 7,793,722.64 | 5,568,574.02 |
| 减:营业外支出 | 336,220.9 | 1,689,269.64 | 1,130,833.69 | 715,224.59 |
| 五、利润总额 | 30,957,297.32 | 76,046,088.16 | 70,118,313.89 | 17,743,361.21 |
| 减:所得税费用 | 7,296,520.81 | 17,509,691.05 | 16,097,927.31 | 3,421,496.13 |
| 六、净利润 | 23,660,776.51 | 58,536,397.11 | 54,020,386.58 | 14,321,865.08 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 23,660,776.51 | 58,536,397.11 | 54,020,386.58 | 14,321,865.08 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 23,262,585.78 | 57,747,287.47 | 53,269,885.92 | 14,024,192.23 |
| 少数股东损益 | 398,190.73 | 789,109.64 | 750,500.66 | 297,672.85 |
| 扣除非经常损益后的净利润 | 546,991.4 | 7,144,899.99 | 9,638,455.72 | 9,012,019.73 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.26 | 0.24 | 0.06 |
| (二)稀释每股收益 | 0.1 | 0.26 | 0.24 | 0.06 |
| 八、其他综合收益 | -2,915,731.79 | 17,005,779.85 | 20,954,541.38 | 5,004,193.22 |
| 归属于母公司股东的其他综合收益 | -2,915,731.79 | 17,005,779.85 | 20,954,541.38 | 5,004,193.22 |
| 九、综合收益总额 | 20,745,044.72 | 75,542,176.96 | 74,974,927.96 | 19,326,058.3 |
| 归属于母公司股东的综合收益总额 | 20,346,853.99 | 74,753,067.32 | 74,224,427.3 | 19,028,385.45 |
| 归属于少数股东的综合收益总额 | 398,190.73 | 789,109.64 | 750,500.66 | 297,672.85 |
| 公告日期 | 2026-04-30 | 2026-04-09 | 2025-10-31 | 2025-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |